Vapotherm, Inc.
Vapotherm, Inc. VAPO Peers
See (VAPO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VAPO | $2.17 | -0.46% | 13.55M | -0.26 | -$8.40 | N/A |
| ABT | $133.36 | +3.73% | 232.03B | 17.32 | $7.70 | +1.71% |
| BSX-PA | $122.18 | +2.37% | 175.45B | 230.53 | $0.53 | N/A |
| BSX | $104.86 | +1.86% | 155.14B | 76.54 | $1.37 | N/A |
| SYK | $392.20 | +1.52% | 149.89B | 52.86 | $7.42 | +0.84% |
| MDT | $86.11 | +2.21% | 110.44B | 26.25 | $3.28 | +3.26% |
| EW | $76.86 | +0.14% | 45.09B | 31.76 | $2.42 | N/A |
| DXCM | $85.67 | -0.98% | 33.59B | 64.41 | $1.33 | N/A |
| STE | $246.79 | +8.48% | 24.25B | 39.74 | $6.21 | +0.90% |
| PODD | $322.02 | +0.19% | 22.66B | 57.92 | $5.56 | N/A |
Stock Comparison
VAPO vs ABT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ABT has a market cap of 232.03B. Regarding current trading prices, VAPO is priced at $2.17, while ABT trades at $133.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ABT's P/E ratio is 17.32. In terms of profitability, VAPO's ROE is +0.86%, compared to ABT's ROE of +0.24%. Regarding short-term risk, VAPO is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BSX-PA Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BSX-PA has a market cap of 175.45B. Regarding current trading prices, VAPO is priced at $2.17, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, VAPO's ROE is +0.86%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, VAPO is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BSX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BSX has a market cap of 155.14B. Regarding current trading prices, VAPO is priced at $2.17, while BSX trades at $104.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BSX's P/E ratio is 76.54. In terms of profitability, VAPO's ROE is +0.86%, compared to BSX's ROE of +0.10%. Regarding short-term risk, VAPO is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SYK Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SYK has a market cap of 149.89B. Regarding current trading prices, VAPO is priced at $2.17, while SYK trades at $392.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SYK's P/E ratio is 52.86. In terms of profitability, VAPO's ROE is +0.86%, compared to SYK's ROE of +0.11%. Regarding short-term risk, VAPO is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs MDT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, MDT has a market cap of 110.44B. Regarding current trading prices, VAPO is priced at $2.17, while MDT trades at $86.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas MDT's P/E ratio is 26.25. In terms of profitability, VAPO's ROE is +0.86%, compared to MDT's ROE of +0.09%. Regarding short-term risk, VAPO is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs EW Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, EW has a market cap of 45.09B. Regarding current trading prices, VAPO is priced at $2.17, while EW trades at $76.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas EW's P/E ratio is 31.76. In terms of profitability, VAPO's ROE is +0.86%, compared to EW's ROE of +0.49%. Regarding short-term risk, VAPO is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs DXCM Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, DXCM has a market cap of 33.59B. Regarding current trading prices, VAPO is priced at $2.17, while DXCM trades at $85.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas DXCM's P/E ratio is 64.41. In terms of profitability, VAPO's ROE is +0.86%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, VAPO is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs STE Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, STE has a market cap of 24.25B. Regarding current trading prices, VAPO is priced at $2.17, while STE trades at $246.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas STE's P/E ratio is 39.74. In terms of profitability, VAPO's ROE is +0.86%, compared to STE's ROE of +0.07%. Regarding short-term risk, VAPO is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs PODD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, PODD has a market cap of 22.66B. Regarding current trading prices, VAPO is priced at $2.17, while PODD trades at $322.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas PODD's P/E ratio is 57.92. In terms of profitability, VAPO's ROE is +0.86%, compared to PODD's ROE of +0.35%. Regarding short-term risk, VAPO is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs PHG Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, PHG has a market cap of 22.46B. Regarding current trading prices, VAPO is priced at $2.17, while PHG trades at $24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas PHG's P/E ratio is 83.72. In terms of profitability, VAPO's ROE is +0.86%, compared to PHG's ROE of -0.06%. Regarding short-term risk, VAPO is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ZBH Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ZBH has a market cap of 19.13B. Regarding current trading prices, VAPO is priced at $2.17, while ZBH trades at $96.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ZBH's P/E ratio is 21.48. In terms of profitability, VAPO's ROE is +0.86%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, VAPO is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ABMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ABMD has a market cap of 17.18B. Regarding current trading prices, VAPO is priced at $2.17, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ABMD's P/E ratio is 65.36. In terms of profitability, VAPO's ROE is +0.86%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, VAPO is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ALGN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ALGN has a market cap of 13.53B. Regarding current trading prices, VAPO is priced at $2.17, while ALGN trades at $186.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ALGN's P/E ratio is 33.95. In terms of profitability, VAPO's ROE is +0.86%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, VAPO is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SNN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SNN has a market cap of 12.59B. Regarding current trading prices, VAPO is priced at $2.17, while SNN trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SNN's P/E ratio is 30.61. In terms of profitability, VAPO's ROE is +0.86%, compared to SNN's ROE of +0.08%. Regarding short-term risk, VAPO is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SWAV Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SWAV has a market cap of 12.57B. Regarding current trading prices, VAPO is priced at $2.17, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SWAV's P/E ratio is 78.76. In terms of profitability, VAPO's ROE is +0.86%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, VAPO is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs PEN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, PEN has a market cap of 10.65B. Regarding current trading prices, VAPO is priced at $2.17, while PEN trades at $275.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas PEN's P/E ratio is 257.07. In terms of profitability, VAPO's ROE is +0.86%, compared to PEN's ROE of +0.04%. Regarding short-term risk, VAPO is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs GMED Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, GMED has a market cap of 7.83B. Regarding current trading prices, VAPO is priced at $2.17, while GMED trades at $57.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas GMED's P/E ratio is 43.15. In terms of profitability, VAPO's ROE is +0.86%, compared to GMED's ROE of +0.05%. Regarding short-term risk, VAPO is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BIO-B Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BIO-B has a market cap of 6.87B. Regarding current trading prices, VAPO is priced at $2.17, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, VAPO's ROE is +0.86%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, VAPO and BIO-B have similar daily volatility (0.00).
VAPO vs BIO Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BIO has a market cap of 6.64B. Regarding current trading prices, VAPO is priced at $2.17, while BIO trades at $243.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BIO's P/E ratio is -3.18. In terms of profitability, VAPO's ROE is +0.86%, compared to BIO's ROE of -0.32%. Regarding short-term risk, VAPO is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BRKR Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BRKR has a market cap of 5.56B. Regarding current trading prices, VAPO is priced at $2.17, while BRKR trades at $36.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BRKR's P/E ratio is 70.56. In terms of profitability, VAPO's ROE is +0.86%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, VAPO is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs GKOS Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, GKOS has a market cap of 5.24B. Regarding current trading prices, VAPO is priced at $2.17, while GKOS trades at $91.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas GKOS's P/E ratio is -40.39. In terms of profitability, VAPO's ROE is +0.86%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, VAPO is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs NARI Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, NARI has a market cap of 4.68B. Regarding current trading prices, VAPO is priced at $2.17, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas NARI's P/E ratio is -59.24. In terms of profitability, VAPO's ROE is +0.86%, compared to NARI's ROE of -0.18%. Regarding short-term risk, VAPO is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs IRTC Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, IRTC has a market cap of 4.50B. Regarding current trading prices, VAPO is priced at $2.17, while IRTC trades at $141.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas IRTC's P/E ratio is -45.06. In terms of profitability, VAPO's ROE is +0.86%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, VAPO is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs INSP Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, INSP has a market cap of 4.41B. Regarding current trading prices, VAPO is priced at $2.17, while INSP trades at $149.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas INSP's P/E ratio is 70.24. In terms of profitability, VAPO's ROE is +0.86%, compared to INSP's ROE of +0.10%. Regarding short-term risk, VAPO is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ITGR Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ITGR has a market cap of 4.15B. Regarding current trading prices, VAPO is priced at $2.17, while ITGR trades at $119.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ITGR's P/E ratio is 55.35. In terms of profitability, VAPO's ROE is +0.86%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, VAPO is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs TMDX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, TMDX has a market cap of 4.12B. Regarding current trading prices, VAPO is priced at $2.17, while TMDX trades at $121.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas TMDX's P/E ratio is 85.78. In terms of profitability, VAPO's ROE is +0.86%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, VAPO is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs AXNX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, AXNX has a market cap of 3.63B. Regarding current trading prices, VAPO is priced at $2.17, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas AXNX's P/E ratio is -709.80. In terms of profitability, VAPO's ROE is +0.86%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, VAPO and AXNX have similar daily volatility (0.00).
VAPO vs PRCT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, PRCT has a market cap of 3.22B. Regarding current trading prices, VAPO is priced at $2.17, while PRCT trades at $58.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas PRCT's P/E ratio is -34.38. In terms of profitability, VAPO's ROE is +0.86%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, VAPO is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs LIVN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, LIVN has a market cap of 2.39B. Regarding current trading prices, VAPO is priced at $2.17, while LIVN trades at $43.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas LIVN's P/E ratio is -10.77. In terms of profitability, VAPO's ROE is +0.86%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, VAPO is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs NUVA Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, NUVA has a market cap of 2.08B. Regarding current trading prices, VAPO is priced at $2.17, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas NUVA's P/E ratio is 75.00. In terms of profitability, VAPO's ROE is +0.86%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, VAPO is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs UFPT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, UFPT has a market cap of 1.88B. Regarding current trading prices, VAPO is priced at $2.17, while UFPT trades at $243.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas UFPT's P/E ratio is 29.90. In terms of profitability, VAPO's ROE is +0.86%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, VAPO is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ATEC Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ATEC has a market cap of 1.86B. Regarding current trading prices, VAPO is priced at $2.17, while ATEC trades at $12.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ATEC's P/E ratio is -11.18. In terms of profitability, VAPO's ROE is +0.86%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, VAPO is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CNMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CNMD has a market cap of 1.85B. Regarding current trading prices, VAPO is priced at $2.17, while CNMD trades at $59.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CNMD's P/E ratio is 16.04. In terms of profitability, VAPO's ROE is +0.86%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, VAPO is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs TNDM Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, TNDM has a market cap of 1.51B. Regarding current trading prices, VAPO is priced at $2.17, while TNDM trades at $22.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas TNDM's P/E ratio is -8.14. In terms of profitability, VAPO's ROE is +0.86%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, VAPO is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs HSKA Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, HSKA has a market cap of 1.31B. Regarding current trading prices, VAPO is priced at $2.17, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas HSKA's P/E ratio is -62.49. In terms of profitability, VAPO's ROE is +0.86%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, VAPO and HSKA have similar daily volatility (0.00).
VAPO vs AORT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, AORT has a market cap of 1.24B. Regarding current trading prices, VAPO is priced at $2.17, while AORT trades at $28.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas AORT's P/E ratio is -56.80. In terms of profitability, VAPO's ROE is +0.86%, compared to AORT's ROE of -0.07%. Regarding short-term risk, VAPO is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs AHCO Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, AHCO has a market cap of 1.22B. Regarding current trading prices, VAPO is priced at $2.17, while AHCO trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas AHCO's P/E ratio is 15.59. In terms of profitability, VAPO's ROE is +0.86%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, VAPO is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SILK Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SILK has a market cap of 1.12B. Regarding current trading prices, VAPO is priced at $2.17, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SILK's P/E ratio is -18.96. In terms of profitability, VAPO's ROE is +0.86%, compared to SILK's ROE of -0.37%. Regarding short-term risk, VAPO is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs FNA Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, FNA has a market cap of 1.10B. Regarding current trading prices, VAPO is priced at $2.17, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas FNA's P/E ratio is -19.83. In terms of profitability, VAPO's ROE is +0.86%, compared to FNA's ROE of -0.36%. Regarding short-term risk, VAPO is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ESTA Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ESTA has a market cap of 1.06B. Regarding current trading prices, VAPO is priced at $2.17, while ESTA trades at $36.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ESTA's P/E ratio is -11.27. In terms of profitability, VAPO's ROE is +0.86%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, VAPO is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs INMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, INMD has a market cap of 1.02B. Regarding current trading prices, VAPO is priced at $2.17, while INMD trades at $14.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas INMD's P/E ratio is 6.60. In terms of profitability, VAPO's ROE is +0.86%, compared to INMD's ROE of +0.25%. Regarding short-term risk, VAPO is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs IART Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, IART has a market cap of 1.01B. Regarding current trading prices, VAPO is priced at $2.17, while IART trades at $13.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas IART's P/E ratio is -34.24. In terms of profitability, VAPO's ROE is +0.86%, compared to IART's ROE of -0.03%. Regarding short-term risk, VAPO is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CSII Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CSII has a market cap of 843.96M. Regarding current trading prices, VAPO is priced at $2.17, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CSII's P/E ratio is -20.83. In terms of profitability, VAPO's ROE is +0.86%, compared to CSII's ROE of -0.14%. Regarding short-term risk, VAPO is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CRY Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CRY has a market cap of 725.15M. Regarding current trading prices, VAPO is priced at $2.17, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CRY's P/E ratio is 425.71. In terms of profitability, VAPO's ROE is +0.86%, compared to CRY's ROE of -0.07%. Regarding short-term risk, VAPO is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SIBN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SIBN has a market cap of 719.58M. Regarding current trading prices, VAPO is priced at $2.17, while SIBN trades at $16.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SIBN's P/E ratio is -22.60. In terms of profitability, VAPO's ROE is +0.86%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, VAPO is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs IRMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, IRMD has a market cap of 684.84M. Regarding current trading prices, VAPO is priced at $2.17, while IRMD trades at $53.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas IRMD's P/E ratio is 34.75. In terms of profitability, VAPO's ROE is +0.86%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, VAPO is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CBLL Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CBLL has a market cap of 635.76M. Regarding current trading prices, VAPO is priced at $2.17, while CBLL trades at $17.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CBLL's P/E ratio is -14.07. In terms of profitability, VAPO's ROE is +0.86%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, VAPO is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs AVNS Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, AVNS has a market cap of 589.61M. Regarding current trading prices, VAPO is priced at $2.17, while AVNS trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas AVNS's P/E ratio is -1.54. In terms of profitability, VAPO's ROE is +0.86%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, VAPO is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs APEN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, APEN has a market cap of 579.72M. Regarding current trading prices, VAPO is priced at $2.17, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas APEN's P/E ratio is -9.43. In terms of profitability, VAPO's ROE is +0.86%, compared to APEN's ROE of -0.85%. Regarding short-term risk, VAPO is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BFLY Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BFLY has a market cap of 567.53M. Regarding current trading prices, VAPO is priced at $2.17, while BFLY trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BFLY's P/E ratio is -7.65. In terms of profitability, VAPO's ROE is +0.86%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, VAPO is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs KIDS Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, KIDS has a market cap of 566.47M. Regarding current trading prices, VAPO is priced at $2.17, while KIDS trades at $22.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas KIDS's P/E ratio is -12.99. In terms of profitability, VAPO's ROE is +0.86%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, VAPO is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs NPCE Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, NPCE has a market cap of 560.20M. Regarding current trading prices, VAPO is priced at $2.17, while NPCE trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas NPCE's P/E ratio is -18.37. In terms of profitability, VAPO's ROE is +0.86%, compared to NPCE's ROE of -2.58%. Regarding short-term risk, VAPO is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BFLY-WT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BFLY-WT has a market cap of 550.71M. Regarding current trading prices, VAPO is priced at $2.17, while BFLY-WT trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, VAPO's ROE is +0.86%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, VAPO is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs RXST Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, RXST has a market cap of 540.88M. Regarding current trading prices, VAPO is priced at $2.17, while RXST trades at $13.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas RXST's P/E ratio is -20.17. In terms of profitability, VAPO's ROE is +0.86%, compared to RXST's ROE of -0.10%. Regarding short-term risk, VAPO is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs AXGN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, AXGN has a market cap of 536.51M. Regarding current trading prices, VAPO is priced at $2.17, while AXGN trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas AXGN's P/E ratio is -73.62. In terms of profitability, VAPO's ROE is +0.86%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, VAPO is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs OFIX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, OFIX has a market cap of 478.01M. Regarding current trading prices, VAPO is priced at $2.17, while OFIX trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas OFIX's P/E ratio is -3.30. In terms of profitability, VAPO's ROE is +0.86%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, VAPO is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BVS Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BVS has a market cap of 433.98M. Regarding current trading prices, VAPO is priced at $2.17, while BVS trades at $6.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BVS's P/E ratio is -13.91. In terms of profitability, VAPO's ROE is +0.86%, compared to BVS's ROE of -0.21%. Regarding short-term risk, VAPO is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs TMCI Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, TMCI has a market cap of 424.61M. Regarding current trading prices, VAPO is priced at $2.17, while TMCI trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas TMCI's P/E ratio is -7.94. In terms of profitability, VAPO's ROE is +0.86%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, VAPO is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SRDX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SRDX has a market cap of 400.81M. Regarding current trading prices, VAPO is priced at $2.17, while SRDX trades at $28.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SRDX's P/E ratio is -20.02. In terms of profitability, VAPO's ROE is +0.86%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, VAPO is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CLPT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CLPT has a market cap of 365.18M. Regarding current trading prices, VAPO is priced at $2.17, while CLPT trades at $12.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CLPT's P/E ratio is -18.46. In terms of profitability, VAPO's ROE is +0.86%, compared to CLPT's ROE of -0.62%. Regarding short-term risk, VAPO is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SENS Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SENS has a market cap of 356.65M. Regarding current trading prices, VAPO is priced at $2.17, while SENS trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SENS's P/E ratio is -4.96. In terms of profitability, VAPO's ROE is +0.86%, compared to SENS's ROE of -7.46%. Regarding short-term risk, VAPO is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs NNOX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, NNOX has a market cap of 347.50M. Regarding current trading prices, VAPO is priced at $2.17, while NNOX trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas NNOX's P/E ratio is -5.99. In terms of profitability, VAPO's ROE is +0.86%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, VAPO is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs OM Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, OM has a market cap of 346.47M. Regarding current trading prices, VAPO is priced at $2.17, while OM trades at $19.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas OM's P/E ratio is -0.68. In terms of profitability, VAPO's ROE is +0.86%, compared to OM's ROE of -1.45%. Regarding short-term risk, VAPO is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CTKB Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CTKB has a market cap of 339.45M. Regarding current trading prices, VAPO is priced at $2.17, while CTKB trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CTKB's P/E ratio is -29.78. In terms of profitability, VAPO's ROE is +0.86%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, VAPO is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs VREX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, VREX has a market cap of 327.44M. Regarding current trading prices, VAPO is priced at $2.17, while VREX trades at $7.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas VREX's P/E ratio is -7.66. In terms of profitability, VAPO's ROE is +0.86%, compared to VREX's ROE of -0.08%. Regarding short-term risk, VAPO is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs PACB Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, PACB has a market cap of 318.09M. Regarding current trading prices, VAPO is priced at $2.17, while PACB trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas PACB's P/E ratio is -0.39. In terms of profitability, VAPO's ROE is +0.86%, compared to PACB's ROE of -1.25%. Regarding short-term risk, VAPO is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SMLR Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SMLR has a market cap of 312.27M. Regarding current trading prices, VAPO is priced at $2.17, while SMLR trades at $32.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SMLR's P/E ratio is 6.34. In terms of profitability, VAPO's ROE is +0.86%, compared to SMLR's ROE of +0.35%. Regarding short-term risk, VAPO is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs VMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, VMD has a market cap of 266.39M. Regarding current trading prices, VAPO is priced at $2.17, while VMD trades at $6.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas VMD's P/E ratio is 22.47. In terms of profitability, VAPO's ROE is +0.86%, compared to VMD's ROE of +0.10%. Regarding short-term risk, VAPO is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CERS Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CERS has a market cap of 246.60M. Regarding current trading prices, VAPO is priced at $2.17, while CERS trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CERS's P/E ratio is -11.73. In terms of profitability, VAPO's ROE is +0.86%, compared to CERS's ROE of -0.35%. Regarding short-term risk, VAPO is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ZIMV Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ZIMV has a market cap of 242.64M. Regarding current trading prices, VAPO is priced at $2.17, while ZIMV trades at $8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ZIMV's P/E ratio is -7.07. In terms of profitability, VAPO's ROE is +0.86%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, VAPO is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs MXCT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, MXCT has a market cap of 237.09M. Regarding current trading prices, VAPO is priced at $2.17, while MXCT trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas MXCT's P/E ratio is -5.57. In terms of profitability, VAPO's ROE is +0.86%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, VAPO is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs TCMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, TCMD has a market cap of 224.35M. Regarding current trading prices, VAPO is priced at $2.17, while TCMD trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas TCMD's P/E ratio is 15.08. In terms of profitability, VAPO's ROE is +0.86%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, VAPO is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs NVRO Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, NVRO has a market cap of 224.09M. Regarding current trading prices, VAPO is priced at $2.17, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas NVRO's P/E ratio is -1.91. In terms of profitability, VAPO's ROE is +0.86%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, VAPO is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs EYES Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, EYES has a market cap of 210.05M. Regarding current trading prices, VAPO is priced at $2.17, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas EYES's P/E ratio is N/A. In terms of profitability, VAPO's ROE is +0.86%, compared to EYES's ROE of -0.26%. Regarding short-term risk, VAPO is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BWAY Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BWAY has a market cap of 188.34M. Regarding current trading prices, VAPO is priced at $2.17, while BWAY trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BWAY's P/E ratio is 55.44. In terms of profitability, VAPO's ROE is +0.86%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, VAPO is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs BDMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, BDMD has a market cap of 183.28M. Regarding current trading prices, VAPO is priced at $2.17, while BDMD trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas BDMD's P/E ratio is 14.77. In terms of profitability, VAPO's ROE is +0.86%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, VAPO is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CATX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CATX has a market cap of 178.52M. Regarding current trading prices, VAPO is priced at $2.17, while CATX trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CATX's P/E ratio is -2.33. In terms of profitability, VAPO's ROE is +0.86%, compared to CATX's ROE of -0.27%. Regarding short-term risk, VAPO is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs SGHT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, SGHT has a market cap of 176.82M. Regarding current trading prices, VAPO is priced at $2.17, while SGHT trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas SGHT's P/E ratio is -3.49. In terms of profitability, VAPO's ROE is +0.86%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, VAPO is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ANIK Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ANIK has a market cap of 175.54M. Regarding current trading prices, VAPO is priced at $2.17, while ANIK trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ANIK's P/E ratio is -18.00. In terms of profitability, VAPO's ROE is +0.86%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, VAPO is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs QTRX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, QTRX has a market cap of 174.73M. Regarding current trading prices, VAPO is priced at $2.17, while QTRX trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas QTRX's P/E ratio is -3.63. In terms of profitability, VAPO's ROE is +0.86%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, VAPO is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs RCEL Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, RCEL has a market cap of 168.39M. Regarding current trading prices, VAPO is priced at $2.17, while RCEL trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas RCEL's P/E ratio is -3.05. In terms of profitability, VAPO's ROE is +0.86%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, VAPO is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs LNSR Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, LNSR has a market cap of 166.45M. Regarding current trading prices, VAPO is priced at $2.17, while LNSR trades at $14.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas LNSR's P/E ratio is -2.90. In terms of profitability, VAPO's ROE is +0.86%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, VAPO is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs TLSI Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, TLSI has a market cap of 165.23M. Regarding current trading prices, VAPO is priced at $2.17, while TLSI trades at $5.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas TLSI's P/E ratio is -3.90. In terms of profitability, VAPO's ROE is +0.86%, compared to TLSI's ROE of +1.14%. Regarding short-term risk, VAPO is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ELMD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ELMD has a market cap of 163.53M. Regarding current trading prices, VAPO is priced at $2.17, while ELMD trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ELMD's P/E ratio is 26.00. In terms of profitability, VAPO's ROE is +0.86%, compared to ELMD's ROE of +0.16%. Regarding short-term risk, VAPO is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs MASS Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, MASS has a market cap of 162.09M. Regarding current trading prices, VAPO is priced at $2.17, while MASS trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas MASS's P/E ratio is -2.13. In terms of profitability, VAPO's ROE is +0.86%, compared to MASS's ROE of -0.13%. Regarding short-term risk, VAPO is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs CVRX Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, CVRX has a market cap of 161.39M. Regarding current trading prices, VAPO is priced at $2.17, while CVRX trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas CVRX's P/E ratio is -2.89. In terms of profitability, VAPO's ROE is +0.86%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, VAPO is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs INGN Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, INGN has a market cap of 154.60M. Regarding current trading prices, VAPO is priced at $2.17, while INGN trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas INGN's P/E ratio is -5.00. In terms of profitability, VAPO's ROE is +0.86%, compared to INGN's ROE of -0.15%. Regarding short-term risk, VAPO is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs AVR Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, AVR has a market cap of 142.68M. Regarding current trading prices, VAPO is priced at $2.17, while AVR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas AVR's P/E ratio is -2.01. In terms of profitability, VAPO's ROE is +0.86%, compared to AVR's ROE of -4.16%. Regarding short-term risk, VAPO is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs LUNG Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, LUNG has a market cap of 137.68M. Regarding current trading prices, VAPO is priced at $2.17, while LUNG trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas LUNG's P/E ratio is -2.37. In terms of profitability, VAPO's ROE is +0.86%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, VAPO is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs PROF Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, PROF has a market cap of 136.14M. Regarding current trading prices, VAPO is priced at $2.17, while PROF trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas PROF's P/E ratio is -3.74. In terms of profitability, VAPO's ROE is +0.86%, compared to PROF's ROE of -0.62%. Regarding short-term risk, VAPO is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs RPID Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, RPID has a market cap of 134.13M. Regarding current trading prices, VAPO is priced at $2.17, while RPID trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas RPID's P/E ratio is -2.83. In terms of profitability, VAPO's ROE is +0.86%, compared to RPID's ROE of -0.56%. Regarding short-term risk, VAPO is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs LUCD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, LUCD has a market cap of 124.97M. Regarding current trading prices, VAPO is priced at $2.17, while LUCD trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas LUCD's P/E ratio is -1.17. In terms of profitability, VAPO's ROE is +0.86%, compared to LUCD's ROE of -4.60%. Regarding short-term risk, VAPO is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs MYO Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, MYO has a market cap of 116.21M. Regarding current trading prices, VAPO is priced at $2.17, while MYO trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas MYO's P/E ratio is -23.07. In terms of profitability, VAPO's ROE is +0.86%, compared to MYO's ROE of -0.36%. Regarding short-term risk, VAPO is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ICAD Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ICAD has a market cap of 107.59M. Regarding current trading prices, VAPO is priced at $2.17, while ICAD trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ICAD's P/E ratio is -18.67. In terms of profitability, VAPO's ROE is +0.86%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, VAPO is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs HJLI Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, HJLI has a market cap of 98.32M. Regarding current trading prices, VAPO is priced at $2.17, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas HJLI's P/E ratio is N/A. In terms of profitability, VAPO's ROE is +0.86%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, VAPO is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs MGRM Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, MGRM has a market cap of 95.99M. Regarding current trading prices, VAPO is priced at $2.17, while MGRM trades at $2.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas MGRM's P/E ratio is -5.33. In terms of profitability, VAPO's ROE is +0.86%, compared to MGRM's ROE of -1.29%. Regarding short-term risk, VAPO is less volatile compared to MGRM. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs ASXC Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, ASXC has a market cap of 94.92M. Regarding current trading prices, VAPO is priced at $2.17, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas ASXC's P/E ratio is -1.12. In terms of profitability, VAPO's ROE is +0.86%, compared to ASXC's ROE of -4.07%. Regarding short-term risk, VAPO is less volatile compared to ASXC. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs OWLT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, OWLT has a market cap of 88.41M. Regarding current trading prices, VAPO is priced at $2.17, while OWLT trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas OWLT's P/E ratio is -3.32. In terms of profitability, VAPO's ROE is +0.86%, compared to OWLT's ROE of +1.37%. Regarding short-term risk, VAPO is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.
VAPO vs XTNT Comparison
VAPO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VAPO stands at 13.55M. In comparison, XTNT has a market cap of 88.39M. Regarding current trading prices, VAPO is priced at $2.17, while XTNT trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VAPO currently has a P/E ratio of -0.26, whereas XTNT's P/E ratio is -5.29. In terms of profitability, VAPO's ROE is +0.86%, compared to XTNT's ROE of -0.27%. Regarding short-term risk, VAPO is less volatile compared to XTNT. This indicates potentially lower risk in terms of short-term price fluctuations for VAPO.